Isolate Data
| Patient | Isolate | Region | Year | Species | Subtype | Source | Clone Method |
| CA1600 | CA10013 | U.S. | 1998 | HIV1 | B | Plasma | None |
Treatment History
| Order | Regimen | Weeks |
| 1 | AZT | 260 |
| 2 | AZT+DDI | 47 |
| 3 | None | 13 |
| 4 | 3TC+AZT+SQV | 21 |
| 5 | 3TC+D4T+IDV | 52 |
| 6 | RTV+SQV | 4 |
| 7 | 3TC+AZT+NVP | 34 |
| 8 | 3TC+AZT | 17 |
| 9 | ADV+D4T+EFV+RTV+SQV | 15 |
Protease Sequence
| PIMajorDRMs | PIMinorDRMs | Polys | UnusualMuts |
| G48V, I54T, V82A | L10I, R57K, L63P, I64L, A71V, I72V, I93M |
| >CA10013| codons 1-99 PQITLWQRPIVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIVGIGGFTKVKQYD QIPLEICGHKVVGTVLVGPTPANIIGRNLLTQMGCTLNF |
RT Sequence
| NRTIMajorDRMs | NRTIMinorDRMs | NNRTIMajorDRMs | NNRTIMinorDRMs | Polys | UnusualMuts |
| M41L, L74I, M184V, L210W, T215Y | D67G, K219E | K103N | V108I | V35M, T39A, E40F, K43E, V60I, S68G, R83K, K104R, V118I, K122E, D177N, T200A, R211K, L228H, T286A, E291D, E297K |
| >CA9947| codons 1-303 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALMEICAFLEEEGKISKIGPENPYNTPI FAIKKKGGTKWRKIVDFRELNKKTQDFWEVQLGIPHPAGLKKNRSVTILDVGDAYFSIPL DEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPNIVI YQYVDDLYVGSDLEIGQHRAKIEELRQHLWKWGFYTPDEKHQKEPPFHWMGYELHPDKWT VQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGAKALTDVIPLTKEAE LEL |
References
| Author | Title | Citation |
| Shulman, NS | Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: Clinical and genotypic predictors of virologic response. | JAIDS, 2000 |
| Wu, TD | Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. | J Virol, 2003 |
| Gonzales, MJ | Protease and reverse transcriptase mutation patterns in HIV-1 isolates from heavily treated persons: Comparison of isolates from northern California with isolates from other regions. | ARHR, 2003 |
| Rhee, SY | HIV-1 protease and reverse transcriptase mutations: Correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. | J Infect Dis, 2005 |